CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of multiple myeloma (MM).
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with multiple myeloma.
  
  LEARNING OBJECTIVES

  • Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) MM.
  • Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered or recommended.
  • Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into clinical algorithms.
  • Recall recently presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
  • Analyze the mechanism of action of, published efficacy and safety findings with and ongoing research evaluating cereblon E3 ligase modulators, and use this information to prepare for the potential clinical availability of these agents for patients with R/R MM.
  • Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly administered to patients with R/R MM.

  ACCREDITATION, SUPPORT AND CREDIT STATEMENT
  In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
  
  PHYSICIAN CREDIT DESIGNATION STATEMENT
  Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity which includes participation in the evaluation components, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS). For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  NURSING CONTINUING PROFESSIONAL DEVELOPMENT
  Successful completion of this nursing continuing professional development activity will be awarded 1.25 contact hours and 1.25 contact hours in the area of pharmacology.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/SOHO2025/Relapsed-RefractoryMM/Sep4/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  CONTINUING PHARMACY EDUCATION
  Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
  Universal Activity Number: JA0007322-0000-25-046-H01-P
  
  For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the National Association of Boards of Pharmacy (NABP) only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CE ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME, NCPD or ACPE information, listen to or view the recording, review the downloadable slide set, complete the post-test with a score of 80% or better (CME and NCPD only) and fill out the evaluation. Evaluation location URLs are noted below:
  CME Evaluations: ResearchToPractice.com/SOHO2025/RRMM/CME (audio), ResearchToPractice.com/SOHO2025/RRMM/Video/CME (video)
  NCPD Evaluations: ResearchToPractice.com/SOHO2025/RRMM/NCPD (audio), ResearchToPractice.com/SOHO2025/RRMM/NCPD/Video (video)
  ACPE Evaluations: ResearchToPractice.com/SOHO2025/RRMM/ACPE (audio), ResearchToPractice.com/SOHO2025/RRMM/ACPE/Video (video)
  
  DISCLOSURE & CONFLICT OF INTEREST POLICY
  Medical Learning Institute Inc (MLI) and Research To Practice (RTP) are committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Meletios-Athanasios (Thanos) C Dimopoulos, MD
  Professor and Chairman
  Plasma Cell Dyscrasias Unit
  Section of Hematology and Medical Oncology
  Department of Clinical Therapeutics
  School of Medicine
  National and Kapodistrian University of Athens
  Alexandra Hospital
  Athens, Greece
  
  Advisory Committees, Consulting Agreements and Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma SA, Takeda Pharmaceutical Company Limited.
  
  Hans Lee, MD
  Director, Multiple Myeloma Research
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Consulting Agreements: Alexion Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Alexion Pharmaceuticals, Amgen Inc, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Rita Kelley Chair in Oncology
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committees: Advisor to AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Johnson & Johnson, Pfizer Inc, Sanofi.
  
  SURVEY PARTICIPANTS — Natalie S Callander, MD, has no relevant conflicts of interest to disclose. Thomas Martin, MD — Consulting Agreements: GSK, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Johnson & Johnson, Sanofi; Data and Safety Monitoring Boards/Committees: Lilly. Surbhi Sidana, MD — Advisory Committees and Consulting Agreements: AbbVie Inc, Arcellx, BioLineRx, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Allogene Therapeutics, Bristol Myers Squibb, Janssen Biotech Inc, Magenta Therapeutics, Novartis; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb.
  
  MODERATOR
  Joseph Mikhael, MD, MEd
  Professor, Clinical Genomics and Therapeutics
  Translational Genomics Research Institute (TGen)
  City of Hope Cancer Center
  Chief Medical Officer
  International Myeloma Foundation
  Phoenix, Arizona
  
  Consulting Agreements: Bristol Myers Squibb, Janssen Biotech Inc, Menarini Group, Sanofi.
  
  PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
  
  This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
  
  Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
  
  This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.
  
  Release date: October 2, 2025
  Expiration date: October 2, 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.